Research graph
References from Canakinumab. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1146/annurev.immunol.021908.132612
10.1146/annurev.immunol.021908.132612 · External reference
10.1056/nejmoa0807865
10.1056/nejmoa0807865 · External reference
10.1056/nejmoa0809568
10.1056/nejmoa0809568 · External reference
10.1016/j.coph.2004.03.010
10.1016/j.coph.2004.03.010 · External reference
10.1084/jem.20050473
10.1084/jem.20050473 · External reference
Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain
2003 · External reference
10.1016/j.brainresrev.2008.12.020
10.1016/j.brainresrev.2008.12.020 · External reference
10.1038/ncprheum0874
10.1038/ncprheum0874 · External reference
10.1002/art.24349
10.1002/art.24349 · External reference
10.2147/btt.s3167
10.2147/btt.s3167 · External reference
10.1038/nm811
10.1038/nm811 · External reference
10.1038/nrd1109
10.1038/nrd1109 · External reference
10.3310/hta8180
10.3310/hta8180 · External reference
10.1016/j.berh.2006.06.004
10.1016/j.berh.2006.06.004 · External reference
10.1111/j.0906-6705.2005.00271.x
10.1111/j.0906-6705.2005.00271.x · External reference
Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis
2005 · External reference
Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis
2003 · External reference
10.1002/art.20944
10.1002/art.20944 · External reference
10.1186/ar1826
10.1186/ar1826 · External reference
Gout—current diagnosis and treatment
2009 · External reference
10.1186/ar2143
10.1186/ar2143 · External reference
10.1002/art.23245
10.1002/art.23245 · External reference
10.1093/rheumatology/kep306
10.1093/rheumatology/kep306 · External reference
Unresolved reference
2007 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1186/ar2438
10.1186/ar2438 · External reference
Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders
2009 · External reference
PK/PD, safety and tolerability of a human anti-IL-1B monoclonal antibody (ACZ885) in healthy subjects
2006 · External reference
Long lasting response to ACZ885 in patients with Muckle-Wells syndrome (MWS)
2008 · External reference
Treatment of Muckle Wells syndrome with a fully human anti-IL-1beta monoclonal antibody (ACZ885)—Initial results from a proof of concept study
2006 · External reference
Treatment of cryopyrin associated periodic fever syndrome with a long-acting fully human anti-IL-1beta monoclonal antibody (ACZ885)
2008 · External reference
10.1084/jem.20082481
10.1084/jem.20082481 · External reference
10.1002/art.24137
10.1002/art.24137 · External reference
Unresolved reference
External reference
10.1056/nejmoa0810787
10.1056/nejmoa0810787 · External reference
A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
2008 · External reference
Unresolved reference
External reference
A monoclonal antibody to IL-1β attenuates the late asthmatic response to antigen challenge in patients with mild asthma
2006 · External reference
10.1136/ard.2006.066381
10.1136/ard.2006.066381 · External reference
10.1016/j.jaad.2006.05.057
10.1016/j.jaad.2006.05.057 · External reference
10.1111/j.1468-3083.2008.02708.x
10.1111/j.1468-3083.2008.02708.x · External reference
10.1126/science.1156995
10.1126/science.1156995 · External reference
